文献速递神经肿瘤

立体定向活检在80岁及以上脑肿瘤患者中的安全性与治疗影响

Safety and therapeutic impact of stereotactic biopsy in very elderly patients with brain tumors.
PubMed 文献 · J Neurosurg · 2025-02-28

该单中心回顾性研究分析了15年间208例80岁及以上新诊断脑内肿瘤患者的立体定向活检资料,组织学诊断率96.2%,活检结果与疑似诊断不一致者11.1%,持续性神经功能缺损发生率1.9%;活检后80.7%接受辅助治疗,KPS≥70%是接受完整辅助治疗的显著预测因素(OR 24.3,95%CI 7.0-84.1;p<0.001),中位总生存期5.6个月。

要点

  • 80岁及以上患者立体定向活检组织学诊断率96.2%,持续性神经功能缺损发生率1.9%。
  • 活检结果与疑似诊断不一致者占11.1%,影响后续治疗管理。
  • KPS≥70%是接受完整辅助治疗的显著预测因素(OR 24.3,95%CI 7.0-84.1;p<0.001)。

核心结论

  • 对80岁及以上脑肿瘤患者行立体定向活检诊断率高、安全性良好,可影响治疗管理和总生存期。
  • 作者认为,必须考虑患者活检前状况,KPS≥70%是该人群活检决策的关键因素。

研究设计与样本

  • 单中心回顾性分析15年间所有年龄≥80岁、因新诊断脑内肿瘤接受立体定向活检的患者病历。
  • 共2350例立体定向脑活检中,208例年龄≥80岁患者共209例次活检(8.9%)。

主要发现

  • 组织学诊断获得率为96.2%,活检结果与疑似诊断不一致者23例(11.1%)。
  • 活检后1.9%的患者出现持续性神经功能缺损。
  • 组织病理诊断后80.7%的病例接受辅助治疗;仅KPS评分≥70%是接受完整辅助治疗的显著预测因素(OR 24.3,95%CI 7.0-84.1;p<0.001)。
  • 自活检起中位总生存期为5.6个月(IQR 2.4-13.5个月);4级胶质瘤、KPS评分<70%和MRI肿瘤对比增强预测更短的总生存期,接受完整一线辅助治疗预测更长总生存期。
  • 在4级胶质瘤患者中,MGMT启动子甲基化者较未甲基化者生存期显著延长(p<0.001)。

临床怎么用

  • 作者认为,对80岁及以上脑肿瘤患者行立体定向活检诊断率高且安全性良好,可影响治疗管理和总生存期。
  • 作者认为,必须考虑患者活检前状况,KPS≥70%是该人群活检决策的关键因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: There is a lack of data regarding the benefit-risk ratio and therapeutic value of brain biopsy in very elderly patients with brain tumors. This study aimed to evaluate the safety of stereotactic biopsy in patients aged ≥ 80 years and assess the impact of the procedure on subsequent therapeutic management and overall survival (OS). METHODS: The authors retrospectively analyzed the medical records of all patients aged ≥ 80 years who underwent stereotactic biopsy for a newly diagnosed intracerebral tumor during a 15-year period at a single institution. RESULTS: During the period, 2350 stereotactic brain biopsies were performed, with 209 biopsies (8.9%) in 208 patients aged ≥ 80 years. Histological diagnosis was obtained in 96.2% of cases. Biopsy results differed from the suspected diagnosis in 23 patients (11.1%). After biopsy, 1.9% of the patients experienced persistent neurological deficit. After histopathological diagnosis, 80.7% of the cases received adjuvant treatment. Only a Karnofsky Performance Status (KPS) score ≥ 70% was a significant predictor of receiving complete adjuvant treatment (OR 24.3, 95% CI 7.0-84.1; p < 0.001). The median OS from biopsy was 5.6 months (IQR 2.4-13.5 months). Grade 4 glioma, KPS score < 70%, and tumor contrast enhancement on MRI predicted a shorter OS. Receiving complete first-line adjuvant therapy predicted a longer OS. In patients with grade 4 glioma, those exhibiting a methylated O 6-methylguanine-DNA methyltransferase (MGMT) promoter demonstrated significantly prolonged survival compared with patients with an unmethylated MGMT promoter (p < 0.001). CONCLUSIONS: Stereotactic biopsy for very elderly patients with brain tumors has a high diagnostic yield and a favorable safety profile, ultimately impacting patients' therapeutic management and OS. Nonetheless, it is crucial to consider the patient's prebiopsy condition. Specifically, a KPS score ≥ 70% was identified as a key factor in the decision-making process for biopsy in this population.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Deboeuf L, Riche M, Malaizé H, et al. Safety and therapeutic impact of stereotactic biopsy in very elderly patients with brain tumors. J Neurosurg. 2025. PMID: 40020233. doi:10.3171/2024.10.JNS241948

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。